GLP-1 weight-loss drug market trends

Overview

The rise of GLP-1 weight-loss drugs, such as Ozempic, has created secondary market opportunities and medical concerns. In the cosmetics sector, the British chemical company Croda has seen a resurgence due to the demand for Volufiline, a skin-plumping ingredient used to mitigate ‘Ozempic face’—a phenomenon of hollow cheeks and sunken eyes caused by rapid weight loss. This demand has been particularly strong in the French and South Korean cosmetic industries.

In Italy, the surge in demand for semaglutide has led to concerns regarding misuse for cosmetic purposes and the emergence of a black market for clandestine injections, which poses risks of counterfeit or improperly stored products. As the obesity medication revolution matures, the pharmaceutical industry is seeing a shift in investor interest toward the hair regrowth market, with companies advancing oral treatments for pattern baldness.

Entities

Novo Nordisk · Citigroup · Wall Street · Ozempic · Veradermics

Timeline

1 day ago

[BUSINESS] 2 sources
Pharmaceutical trends shift from weight loss to hair regrowth
Following the weight-loss drug boom, the pharmaceutical industry and Wall Street are pivoting toward the massive hair regrowth market, amid rising concerns over Ozempic misuse in Europe.
8 days ago

[BUSINESS] 3 sources
Croda finds new growth treating Ozempic-related facial side effects
UK chemical company Croda is seeing a sales surge after its skin-plumping agent, Volufiline, was found to treat facial hollowing associated with Ozempic use.

Sources

affaritaliani.it · americanindependent.com · brisbanetimes.com.au · dilei.it · m.smh.com.au · panorama.it